Christopher O’Donnell, Ph.D.
Christopher O'Donnell, PHD is Executive Director, WRD and Principal at Pfizer Ventures. Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer's investments in Adapsyn, Kymera, Morphic, Petra, Storm Therapeutics, and Strata Oncology.
Chris brings 19 years of scientific leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams. He most recently built and led the Applied Synthesis Technologies group within R&D to help accelerate the delivery of Pfizer's small molecule portfolio. Prior to that, Chris built and led Pfizer's Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 7 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates.
Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison.